Ex Parte Gupta et al - Page 8

               Appeal 2007-1026                                                                       
               Application 10/405,819                                                                 

               several culturing steps, which includes culturing on maintenance medium.               
               See summary of Pullman, supra at pp. 3-4.  Thus, although Example 2 may                
               not disclose which maintenance medium was used, surely the embryos were                
               cultured on a maintenance medium.  Appellants do not dispute this fact.  The           
               only question is what maintenance medium was used in Example 2.  As                    
               discussed supra, there are three preferred choices.  For the condition                 
               described in Example 2 where the embryos were cultured on a development                
               medium without GA, the skilled worker would immediately envision three                 
               methods:  using a development medium without GA preceded by a                          
               maintenance medium with either 1) GA and ABA, 2) GA alone, or 3) ABA                   
               alone – the latter method which would meet the requirements of claim 1.                
                    We emphasize that there is no requirement in the law for a single                 
               working example to disclose a claimed method in order to find anticipation.            
               For example, anticipation has been found in circumstances where the                    
               anticipatory species was not specifically named in the reference, but could            
               be envisioned within the disclosed genus by the skilled worker upon reading            
               the reference’s description.  See In re Petering, 301 F.2d 676, 681, 133               
               USPQ 275, 279 (CCPA 1962); In re Schaumann, 572 F.2d 312, 315, 197                     
               USPQ 5, 8 (CCPA 1978); Sanofi-Synthelabo v. Apotex Inc., 470 F.3d 1368,                
               1377, 81 USPQ2d 1097, 1102-03 (Fed. Cir. 2006).                                        
                    For the foregoing reasons, we affirm the rejection of claim 1.  Claims            
               7-9, 16-27, and 29 fall with claim 1 because they were not separately argued.          






                                                  8                                                   

Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next

Last modified: September 9, 2013